Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everyone. My name is Gisli Hennermark. I'm the CEO of Surgical Science, and I have with me Anna Ahlberg, the CFO. We will run for you. We will run through a few slides and provide some general comments. And then we will open up for questions and finish by no later than 12:00. Edu Products had a turnaround in the second quarter of this year. -13% may not sound like a turnaround, but it is significant. After a slow start to the quarter, there was a clear shift in momentum, and this trend has really continued into the third quarter. Big tenders are back. Um, and for those of you who were with us on our last call, you remember how important it is that we have this base of revenue from big tenders. And they're back. Um, especially in Eastern Europe. A lot of EU money is being channeled into large projects there. We also see a bright spot in China, where we had a strong, solid quarter. After a number of quarters with difficulties. It's looking better, but it's a little too early to tell because China is hard to predict. Um, the big picture here, and it's always easier to understand it in the reverse mirror, is that 2023 inflation really took off. All the hospital budgets essentially went bust. Our customers did not stop buying, and there was a Q4 effect. Get into 2020 for new budgets. People are naturally very hesitant and cautious. But now inflation is down. Governments are spending money and daring to put their foot on the gas pedal again. And we're definitely seeing it in our sales and we're seeing it in our pipeline. We have good visibility of the coming quarters in our pipeline and the full year 2024. If we look at that, let's start by looking at the full year of 2023. It was 518 million Swedish crowns in educational products. And so far in 2024, after six months, we have 189 million Swedish crowns. So basically, we need to do 165 multiplied by two to reach 330 and then proceed further to achieve 518. This is doable given the pipeline and also one specific large tender that we've been working on for quite some time, but it is uncertain. It also depends a lot on deliveries. When the order is close and when we're able to ship and so on. So this is a change from what we said in the last quarter. But it's still doable. However, there is uncertainty. Moving on, Industry OEM at plus 15% here. It's extremely gratifying to see that our strategy is working. We have said that a number of times, but now it shows in the numbers. We actually tripled the sales of simulators compared to the same period last year, and simulators in this business area consist of specific product-specific simulators for medical device companies. We see no change going forward in this strong demand. So our strategy of having global key account teams and the recruitments we made into that team, and working with the largest med device customers to really serve them, is working. And, it's very gratifying to see. This is despite the fact Industry OEM is growing, despite the fact that license revenue was down 9 million Swedish crowns quarter over quarter. In this area, we see new entrants coming to market that are undergoing their regulatory approvals, perhaps making adjustments to the robots, but also, most importantly, facing the same hospital market and hospital budgets as we have. The consumption of licenses has been slower than expected in early 2024. And remember, these new entrants, they buy licenses from us in bundles, in packages and then they use them and then they buy new packages. So this is a bit bumpy when it comes to the market leader Intuitive. They've had a fantastic launch of the da Vinci 5. And they also said publicly that this is a controlled rollout of the Da Vinci 5. So it's for close customers who are selected partners, many of whom have been working with Intuitive to do the regulatory approvals that are now the customers, and they are preparing for the larger general rollout in 2025. So in this controlled rollout, there is no simulation on the da Vinci 5. This is natural because these are customers that are very familiar and have worked very closely with Intuitive on the da Vinci 5. And when they are moving into next year, they will do a number of hardware and software upgrades and simulation is one of them. Da Vinci 5 robots from this year as well as going forward will be equipped with simulation. So overall our picture is 67 million. License revenue is down a bit. A bit of a headwind from the new entrants. And there is no revenue from the da Vinci 5. But it's not lost revenue, because that will be an opportunity when the da Vinci 5 is launched in 2025. If we look more broadly at robotic surgery, the SRS conference, the Society of Robotic Surgery, just took place at the end of June. It's never been bigger, with more players, more participants, and great technological advancements being presented. It was a massive success for da Vinci 5. A lot of new entrants, particularly Asian companies, continue to enter the market. And we will also see continued consolidation, which has just started in this market. We had a fantastic SRS. We had our new ultra-portable head-mounted display extension as well, but basically, we use the same simulation software that our partners have on their robotic consoles in a head-mounted display so they can get more value out of the simulation and we can generate more license revenue. We have now received the first test order for this product, which will be delivered in Q3. We also signed with a new robotic customer, a European one, which will generate both license and development revenues.
And, uh.
This is my 28th quarterly report as CEO. It's now time for me to hand the company over in really good hands. Tom England. I'm looking at him right now. He's here in the studio with us. Even though he's not miked up. We will now have time to work side by side. I will lead the company up until October 1st, and then Tom takes over. So that feels really good. We are confident that we are in the very early phases of simulation because if you look at digitalization, how we can utilize our software on medical device companies' own platforms, robotic surgery is just the first step there. And we are doing amazing work with our educational customers and in our educational products, and there is really strong synergy between the two areas. So I feel very good and I'm very proud of what the team and I have accomplished in the last nine years, and I am very happy to hand it over to Tom. After our 2026 goals, we still have a couple of years to go, and then Tom will shape and lead us into the future. And with that, I hand over to Anna.
Thank you very much. Hi, everyone. So I will dig into the numbers a bit more, starting with the revenues. As we talked about, we saw a rebound for Edu Products, especially towards the end of the quarter. Ind/OEM continued to show very strong development, with many interesting orders and prospects both outside of and within robotics. We also signed with new customers, as Gisli previously mentioned, even though of course it does not show in this quarter's numbers. In total, for the quarter, we had sales of 212 million SEK. Indeed, that was down 2%, and in local currency, it was down 1%, while Edu Products were down 13% versus Q2 last year, but up 39% versus Q1. And as mentioned, Asia, and especially China, had a strong quarter; China is a very important market for us within educational products. So, it's of course important, even if it is a bit early, to state that this will continue and that there are no further effects from the anti-corruption campaign that has impacted us for quite some time. Large tenders are back, and we see several that should be closed during this year. Ended the quarter strong with a good order book, a larger order book going out of the quarter than coming into it. And Q3 has continued. On the same note, the industry was up 15%. License revenues were down, and the reasons for this were explained in relation to the simulator. Sales continue to be very strong, as does development revenue. So I will talk a bit more about them on the next slide. In total, the industry OEM accounted for 40% of our total sales and educational products constituted 52%. Looking then at our four different revenue streams that we report on, and in the report, you also have them divided by business area: license revenues, as mentioned, are down 9 million SEK and constitute 32% of our total revenues. Emphasizing again that they are lumpy for new entrants since they purchased the licenses in packages or batches, and some that have bought these packages have used less than expected during the first half of the year. And that is then impacting, of course, new orders. We now see revenues from several customers within this revenue stream. Simulator sales have rebounded from the first quarter. Edu Products increased 62%, and Ind/OEM continued, even though it was down a bit from Q1. Continued the very strong development. We also mentioned that this part is a bit more bumpy, as these projects include both product sales and development revenues, with development revenues being higher and consisting of both robotics projects as well as what I just stated, sales of simulators in the OEM area. Service revenues continue to be stable and are growing over time with a larger installed base. Costs and margins for the quarter. We continue to have good cost control. Q3 was a quarter of high activity, resulting in higher operational expenditure (opex) costs compared to Q1. And also, compared to Q2 last year, they were higher, reflecting the fact that we are a growing company. We have more employees. We see inflation in areas such as wages. This quarter, we also incurred some costs that were more of a one-off or rare nature, such as CEO recruitment costs. Sales costs then accounted for 20% of our sales for the quarter, administrative expenses were 10%, and R&D was on par at 23% of sales, with cost activations on our balance sheets just below 10 million. That was approximately the same as last quarter. Our gross margin remained consistent with last year and showed improvement over Q1. The decreased share of license revenues had a negative effect on the gross margin. While we had a good product mix, the average sales price also affected the margin positively. The operating result ended at 33 million SEK, or a margin of 16%. Looking at our organization, we had the same number of employees at the end of Q2 as we did at the end of Q1, and that was six more than in Q2 of last year. And down to the right, you can see the split between our different sites. Adjusted EBIT, where we have our financial goal of 40% in 2026, and where we add back amortization on acquisition-related items to our EBIT, was 19% for the quarter, up from 17% in Q1. For the first six months, it was 18% or 72 million SEK. Our finance net for the quarter was a positive 4.4 million SEK, primarily from interest on our bank balances. That was 4.7 million SEK. And then, we have some revaluation items on internal loans and also the IFRS 16 effect from last year. So, in the comparison numbers, we also had a revaluation effect on the contingent consideration for the Mimic acquisition. I will talk a bit more about that under cash flow. The net result for the quarter was 29 million SEK. And looking at the cash flow, we had really tough numbers to compare against. Q2 of last year was an all-time high. From operating activities, we gained 30 million SEK, and included in that number is a negative for working capital of 17 million SEK. We increased our inventory. A large part of that was due to higher inventory of finished goods and work-in-process. Our accounts receivable, however, decreased. And as you can see from the gray line, it continued to decrease as a percentage of the last 12 months' sales. Cash flow from investing activities primarily consists of investments in development.
Costs.
And then from financing activities. There we had the payout of the last part of the contingent consideration for the Mimic acquisition. That was 1.1 million USD, or approximately 12 million SEK. It didn't affect the income statement. It was booked in Q4 last year, but it was paid out during Q2 and then Q2 last year. Instead, we had a positive item of 19 million SEK attributable to the redemption of an options program. We ended Q2 with cash and bank balances amounting to $667 million. And with that, we will open up for questions.
If you wish to ask a question, please press Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please press Pound Key six on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Please go ahead.
Thank you very much.
It's an honor. And before we continue,
actually, before Ulrich, before you get going with your question, I see I've received a number of questions on the same theme here in the chat asking about how much revenue we will get from da Vinci 5. Why wasn't simulation included from the start? I just want to make a general comment to those questions, because perhaps many of those calling in have similar inquiries. There has been no change to the plan. We can only comment on what our customers are publicly stating. And now we're very pleased that Intuitive made a comment during their Q2 call. So, it is part of their plan not to have simulation included initially. On the controlled rollout, select close customers of Intuitive are getting access to the da Vinci 5 and simulation will be included starting early 2025. These units will then be equipped with simulation. I cannot comment specifically on how much revenue this will generate for us; I can only conclude that our license revenue of 67 million in this quarter, given the fact that we did not get license revenue on da Vinci 5, and that some of the new entrants have had a slower start to 2024, makes us very comfortable with what we're seeing going forward. So this has nothing to do with Surgical Science. It's not that we were late with the simulation integration or anything like that. We are working very closely. Our teams are working very closely with Intuitive. We have one big team heading out to California in a couple of weeks, and everything is progressing exactly according to plan. Sorry, but I just wanted to get that out of the way. And then I hand over to you.
Sure, thank you. I had a few other questions in mind to start off with, but since you mentioned the da Vinci 5 shift, and my interpretation of listening in to the Intuitive Q2 call was that they will be integrating more simulation into their systems going forward versus historically. So first of all, is that a fair assumption? And secondly, I know that you don't want to discuss specifics about Intuitive, but do you see a general trend of including more basic training in the robots or even advancing to include more complex simulations? And do you believe that, if volumes were to increase and basic simulation were to be integrated, that it would impact your average selling price, or would it be neutral for the margins?
Yeah, thank you, Ulrich. Many questions there, indeed. Let me see where to start with this. First of all, David Röszā, president of Intuitive, stated that simulation will be integrated. He didn’t specify any quantity, more or less, etc. Then, when it comes to general robotic surgery, what we see at SRS and elsewhere is that more players in this market are increasingly integrating simulation with the complete ecosystem. And this was exactly what Intuitive commented on, discussing how it integrates into case insights and other parts of their ecosystem. And, to address your question, the greater value you provide as a partner, the more money you generate, and as a company, we continue to develop newer, better technologies and innovations. Because we operate one of the best R&D organizations, and we also have the scale to do this as we collaborate with many robotic companies. This results in a network economy effect because we continuously enhance our intellectual property and bring new solutions to help surgeons increase patient safety by training in a safe, controlled environment where they receive objective feedback. I can't comment specifically on Intuitive, but generally, the more value you add, the more money you earn. And this is what we foresee going forward.
Great. Thank you. If we focus on the OEM side of the business, and as you mentioned, it appears that demand, generally outside of robotics, is accelerating. You also introduced a new strategy on your end. Is there more to that? Are customers seeking more simulations to showcase their devices, or have there been large projects now materializing? Can you clarify the margin profile of OEM revenues outside of robotics, and since you're also selling hardware, albeit a small portion to robotic surgery companies, could you discuss the growth trends on your end toward these companies, or should we focus more on license revenues and view it from a rolling 12-month perspective? Could you assist us with understanding this approach?
Yeah.
Let me see if I begin with the first part of the question regarding the industry or OEM.
Or maybe just start with the second part just so we ensure this clarification is understood in context outside of robotics, where there is no hardware involved. It continues to be purely software, including development revenues and license revenues. So this applies to customers outside of the robotics field. In these cases, it involves both hardware and software, and more product-specific, tailor-made solutions either based on the simulators we have, then we do development work to make them product-specific. Or, as we also mentioned in the report, with our broad product range we can combine and create completely new solutions. This is largely about a market where we are finding new solutions and new approaches.
Customers are also increasingly using simulation for a variety of purposes. Of course, a natural application is training end users to increase patient safety, but they also employ it in sales and marketing, as well as in R&D to test concepts early on. So we see a continued adoption and utilization of simulation technology broadly speaking, and our strategy is truly effective following our consolidation of specific technology niches to become this comprehensive simulation provider in healthcare for these kinds of applications where we currently offer solutions.
To clarify, would you say that there has been a shift towards customers now desiring more simulation for their specific devices? This seems to be the case, based on your comments from the last few quarters, indicating an acceleration in demand for this customer group. Also, the initial question asked how the margin profile looks compared to your license business margins.
It's not the same as license revenues, but it includes hardware as well. But it is definitely a high-margin business that also shows growth in volume and the like. We see that, but of course, it's not the same as licenses.
No. And in my CEO commentary, I noted that it's challenging in these specific deals to estimate production time and development because these solutions are more tailor-made. We have been very successful in bringing to the customers' attention that these technologies exist and how they can benefit from them. And that approach is paying off. We have also observed that this strategy is effective. Looking back at the past few quarterly reports, you can now see its impact in the numbers, and we believe there is significant potential for further growth in this area. We truly believe the demand in this sector will not decline.
Great. That was the last question I have. In terms of education, there has obviously been sequential improvement, which was somewhat anticipated based on our Q1 comments. Now, you mention that procurements are rebounding strongly, particularly driven by activity in Eastern Europe, and you discuss significant tenders that could potentially stabilize the year-on-year full-year results. Could you provide more details on these tenders, and specifically, are they on par with the levels seen in 2023, or are they larger?
We now conclude that there has definitely been a turnaround. Indeed, Educational Products have rebounded significantly. It's very clear from what occurred at the close of Q2 and how Q3 has begun. The start of Q3 has been exceptionally strong. July, typically a quiet month, has been unusually busy this year. Regarding our pipeline, we haven't specified how many tenders there are, but it's clear that Educational Products are poised for strong performance moving forward. Achieving growth in 2024 is feasible, but it's a race against time. That's what we can assert at this point. Okay.
Okay, great. That concludes all my questions. Thank you very much.
Thank you.
Thanks.
The next question comes from Viktor Hojbjerg of Danske Bank. Please go ahead.
Regarding education, let's discuss the unusually large tender you mentioned. This tender could significantly impact growth in this segment for the entire year. Could you quantify how large that tender is?
No, I don't want to quantify it. I just want to add that, you know, it is a race against the clock. We see our pipeline and say, okay, we can make it. But, you know, it depends on deliveries when we get the PO, etc., etc. It's tight; it's uncertain. And on the margin there, it's one specific large tender that we've been working on for a long time that we hope will come through. And as we've said now, we will surely comment on it in the future.
And it's fair to assume that if you wouldn't be able to fit it in this year, it would.
Be in, in, in the next year. Or would it be sort of a new one, thinking about winning it or considering the timing for it?
No, I mean, nothing is a sure thing until it's signed. Of course, we have high hopes of winning it.
Okay, another question on educational. So, if you could just help us understand the growth turnaround here during the quarter, you said that the start of Q3 has been strong as well, down just 13% year over year in the full quarter versus 45% in Q1. So it looks like they actually grew in June and definitely in July. Is that the correct assumption that you're back to growth?
Um, I mean.
We don't focus on specific months in that way for us. And as you know, a lot.
Usually, a lot of orders come towards the end of the quarter. So, it doesn't really make sense. We know what we said before. We know that we have good visibility of the pipeline. Uh, and yes, we have had a good closure at the end of Q2 and the beginning of Q3, but that's not something I will discuss further. No, we can't provide those numbers.
Just a final note on the non-robotic simulator sales. Uh, that's been growing strongly, and thus the traction you're getting with your clients is apparent. Does this affect your cost or investment plan going forward? Do you want to or do you need to put additional resources into this to be able to manufacture and also develop these products?
We have made the investment in the sales force, and we have discussed that, and you have seen it reflected in the numbers. I think our EVP of that area, Nicholas Olsen, has done a great job in forming this truly global team. We are now beginning to see the fruits of that work. When it comes to other parts of the business, it's part of the overall growth plan to develop work, then assemble simulators, ship them, install them, and service them. It's business as usual. And it's part of the overall growth plan.
Okay. Thank you very much.
Thanks.
The next question comes from Christian Binder from Redeye. Please go ahead.
Hi.
And thank you so much for taking my questions. Just to follow up on the increased simulator sales in the Ind/OEM sector. Did you expect that increase over time when you set your margin target for 2026, or might that affect your margin outlook if that trend continues?
You know, we set the strategy almost two years ago. And so, this is of course something that was in the plan. We've stated for quite some time that with this new strategy, we also expect growth within the non-robotic area. How much it is, is not something that we typically comment on. But again, we've said it for quite some time, and we are very happy that it's now also starting to show in the numbers.
It also shows the strategic importance of having the two pillars of educational products, where we gain close key opinion leadership contacts. We sell simulators to academia, primarily to university hospitals. We learn a lot; we then develop product-specific simulators for the medical device companies. And, we are often able to enhance our IP, which flows back to educational products. To a large extent, it's the same resources in development, final assembly, QA, QC, and logistics. It's really great to have these two pillars to stand on. Now, industry OEM has been really strong at the beginning of the year. Educational products have been slow. Now educational products have turned around, and we see no signs of a slowdown in the industry thus far.
Perfect. And just in general, when it comes to the robotic surgery industry, you mentioned that several potential new entrants have experienced delays. And there's also this ongoing consolidation. Um, when you look back a couple of years, would you say that now it looks like the market may support fewer players? And how is that going to affect your competitive situation?
For us, the really important sort of KPI.
Is.
Number of robotic procedures that really drive our business because that drives the underlying need for training. Additionally, if you delve deeper, it also varies depending on the type of procedures. Because if you're venturing into new areas that we're seeing now, you're using the robots for different kinds of indications that you weren't before. It continuously drives the need for training in order to secure patient safety. Also, new instruments and new technologies. New features being added to the robots require controlled simulated training, combined with the ESG aspect where more and more companies do not want to conduct training with live animals or cadavers. So, uh, this is the overall picture, Christiane.
Okay, perfect. That was up from my side.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Kristian Lee from Perito Securities. Good morning, everyone, and thank you for joining the Q2 2024 interim report webcast for Surgical Science.
Thank you, and good morning. Um, I had two questions, please. Based on their current order book, they expect educational products to return to growth in Q3. Or do you need to win a larger procurement?
We haven't commented specifically on that. Christiane, what we have said is that we see a very clear comeback, a rebound, and large tenders and a really strong finish to Q2. We have also commented that Q3 started very strong and that we have a really healthy, solid pipeline, providing a clear view of our deal flow going forward. You also noted that our inventory went up, and we commented that it was primarily finished goods. So these factors indicate that we anticipate a strong comeback during the year for educational products. But we are also very clear on the fact that last year it was 518 million. So for six months, it's 189. Basically, in order to achieve growth, we need to do around 165 per quarter. And we're uncertain if we will reach there. But it's doable.
Very clear. Thank you. Uh, and I was also wondering if you could give us some more color on the simulation that will be included in the da Vinci 5. Uh, will it only be training of basic skills, or, uh, will more advanced procedures also be included in this package?
I wish I could do it, Christian, but we are very mindful of our customer confidentiality. And as our customer in this case has not made any comments around it other than that specific comment they made during their own Q2 call. I cannot comment on that.
Okay. Fair enough. Thank you very much.
Okay, so no more questions there. And I think we answered the written questions as well during this.
The question.
Session.
So thank you very much everyone who called in. And thank you everyone who contributed with the great questions. And uh, with this, we then, uh, give you guys 15 minutes of your time back and conclude today's call. Thank you very much.
Thank you.



















